CryoLife, Inc. (CRY)
Acquisition of Hemosphere, Inc by CryoLife, Inc. Call
May 15, 2012 11:00 am ET
Steven G. Anderson – Chairman, President and Chief Executive Officer
D. Ashley Lee – Executive Vice President, Chief Operating Officer, Chief Financial Officer and Treasurer
Jeffrey S. Cohen – Ladenburg Thalmann & Co.
Matt Dolan – Roth Capital Partners
Raymond Myers – The Benchmark Company, LLC
Greetings and welcome to the CryoLife Update Conference Call. At this time, all participants are in a listen-only mode. A brief question-and-answer session will follow the formal presentation. [Operator Instructions] As a reminder, this conference is being recorded.
It is now my pleasure to introduce your host, Steve Anderson, President and CEO for CryoLife. Thank you, Mr. Anderson, you may begin.
Steven G. Anderson
Good morning, everyone, and welcome to CryoLife’s Hemosphere acquisition conference call. This is Steven Anderson, CryoLife’s President and CEO. I’m joined today by Ashley Lee, CryoLife’s Executive Vice President, COO and CFO. We’d like to thank you for joining us on this call to discuss the acquisition of Hemosphere that we announced earlier this morning.
Before going farther, I want to remind everyone that we posted a slide presentation to accompany this conference call in the Investor Relations section of our corporate website at www.cryolife.com. If you have not done so already, I encourage you to download these slides now.
The agenda for today’s call is as follows. I will open the call with some comments about the acquisition of Hemosphere and its strategic fit with CryoLife and the acquisition strategy that we have been working on for some time. Ashley will follow these comments with a detailed overview of the HeRO Graft business, the incremental opportunity it opens for CryoLife and the financial details of the transaction. After Ashley’s comments, we will open the call for questions.
Check Out Our Best Services for Investors
Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts